CoQ10 (coenzyme Q10) is a naturally occurring compound, synthesised endogenously and found in small levels in an average diet. Found predominantly in the mitochondria of the cells, this important enzyme plays a key role in energy production and is vital for ensuring normal everyday functioning. In addition to its role in energy production, CoQ10 is a potent antioxidant and is also able to regenerate other antioxidants including vitamin E, vitamin C and lipoic acid. Its ability to quench free radicals is, in fact, key to maintaining the structural integrity and stability of mitochondrial and cell membranes.  CoQ10 levels generally peak around the age of 20-30 and decline with increasing age. Significantly decreased levels of CoQ10 are found in a wide variety of diseases, especially those associated with oxidative stress  as wells in individuals using statins for cholesterol management. Also known as HMG-CoA reductase inhibitors, statins treat elevated blood cholesterol levels by blocking cholesterol biosynthesis. In doing so, however, they also block CoQ10 biosynthesis, which may lead to symptoms of fatigue and muscle pain (known as statin-induced myopathy). 
Ubiquinone and ubiquinol
CoQ10 exists in two forms, as ubiquinone (the oxidised CoQ10, spent form) and ubiquinol (the reduced and activated, antioxidant form). In order for CoQ10 to play a role in energy production and exhibit an antioxidant effect, the body must metabolise it to its antioxidant form ubiquinol, a process inhibited with increasing age, nutrient deficiency and some health conditions. Taking CoQ10 as ubiquinone is therefore not as effective as taking CoQ10 as ubiquinol (Kaneka QH™) the ‘body-ready’ form which has only been available for use in supplements since 2006. Ubiquinol has numerous advantages over ubiquinone and comparing the two forms in therapeutic outcomes far surpasses its oxidised precursor.
When addressing the issue of therapeutics, at first glance the dose of ubiquinol may seem particularly relevant; however, it is the blood plasma level achieved by supplementation that is the significant factor in determining the effectiveness of a treatment.  As a lipid-soluble nutrient, ubiquinol absorption and bioavailability is generally poor, with as much as 60% eliminated in the faeces.  Whilst the structure of ubiquinol renders it more water-soluble than ubiquinone, most common formulations of ubiquinol (found in powder form or dispersed in oil suspensions) are of relatively low bioavailability.  As clinical outcomes are dependent on increasing the bioavailability, solubilising ubiquinol is the only method to guarantee that therapeutically viable blood plasma levels are achieved.
VESIsorb® for unprecedented bioavailability
Ubiquinol that utilises the VESIsorb® technology offers unprecedented bioavailability to deliver plasma levels superior to all other forms of CoQ10.  When in contact with the aqueous contents of the stomach, this novel delivery system naturally self-assembles into colloidal droplets (micro-emulsion), engulfing the ubiquinol, which is then able to completely dissolve in water. By doing so, ubiquinol is effectively fast-tracked from the gut lumen, through the unstirred water layer barrier that lines the gut wall, directly into the enterocyte cell for immediate transfer to the circulatory system.
Igennus VESIsorb® Ubiquinol-QH
Igennus VESIsorb® Ubiquinol-QH ensures significantly higher plasma concentrations that reach therapeutic levels up to 2 times faster and are sustained for up to 6 times longer than any other delivery system or form of CoQ10. Unlike other delivery forms of CoQ10, this highly advanced delivery system achieves and maintains clinically effective plasma concentrations of CoQ10, supporting cardiovascular function, energy production, reduce the risk of neurodegenerative disease and provide potent antioxidant activity with just one 100 mg capsule daily.
1. Rauchova H, Drahota Z, Lenaz G: Function of coenzyme Q in the cell: some biochemical and physiological properties. Physiological research / Academia Scientiarum Bohemoslovaca 1995, 44:209-216.
2. Potgieter M, Pretorius E, Pepper MS: Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutrition reviews 2013, 71:180-188.
3. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ: Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. Journal of clinical pathology 1993, 46:1055-1057.
4. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, et al: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of neurology 2002, 59:1541-1550.
5. Wyman M, Leonard M, Morledge T: Coenzyme Q10: a therapy for hypertension and statin-induced myalgia? Cleveland Clinic journal of medicine 2010, 77:435-442.
6. Bhagavan HN, Chopra RK: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free radical research 2006, 40:445-453.
7. Liu ZX, Artmann C: Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system. Alternative therapies in health and medicine 2009, 15:42-46.